Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

High-throughput methods to investigate tumour omic landscapes have quickly catapulted
cancer specialists into the precision oncology era. The singular lesson of precision oncology …

Cancer immunotherapy works by stimulating and strengthening the body's anti-tumor
immune response to eliminate cancer cells. Over the past few decades, immunotherapy has …

Malignant transformation of cells depends on accumulation of DNA damage. Over the past
years we have learned that the T cell–based immune system frequently responds to the …

Despite unprecedented responses of some cancers to immune checkpoint blockade (ICB)
therapies, the application of checkpoint inhibitors in pancreatic cancer has been …

Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of childhood
cancer-related death. Prior studies have shown clonal mutations at relapse often arise from …

Sarcomas are a group of diverse and complex cancers of mesenchymal origin that remains
poorly understood. Recent developments in cancer immunotherapy have demonstrated a …

Simple Summary Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment
of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients …

Immunotherapeutic manipulation of the antitumor immune response offers an attractive
strategy to target genomic instability in cancer. A subset of tumor-specific somatic mutations …

Simple Summary Here, we review the current state of knowledge in the field of cancer
immunotherapy, focusing on the scientific rationale for the use of oncolytic viruses …